Monitor upcoming 2027 biosimilar launches and any new in-licensing deals that expand the pipeline beyond the current 4-product portfolio. The $20-25M 2030 revenue target implies a ~5-6x revenue ramp from 2026 levels, which will require consistent execution on regulatory approvals and market access.
Price Chart
Executive Summary
Kamada announced the commercial launch of two new biosimilars in Israel (Ustekinumab-Kamada and Enoxaparin-Kamada), expanding its biosimilar portfolio to four marketed products. The company expects biosimilar sales of ~$4M in 2026, growing to ~$10M by 2028 and $20-25M annually by 2030, positioning this as a meaningful growth driver alongside its core plasma-derived portfolio.
Key Facts
- Launched two new biosimilars in Israel: Ustekinumab-Kamada (biosimilar to Stelara) and Enoxaparin-Kamada (biosimilar to Clexane).
- Biosimilar portfolio now includes four marketed products; expects at least two additional launches in 2027.
- 2026 biosimilar sales guided to ~$4M, growing to ~$10M in 2028 and $20-25M annually by 2030.
- Portfolio targets chronic immune-inflammatory diseases, thromboembolic disorders, oncology, and supportive care.
- Kamada expects 12 marketed biosimilars from 6 licensing partners by 2030, with additional candidates in development/registration.
Financial Impact
Biosimilar revenue expected to grow from ~$4M in 2026 to $20-25M annually by 2030, representing a meaningful new revenue stream.
Risk Factors
- Biosimilar competition in Israel and MENA region may pressure pricing and market share.
- Geopolitical risks from Middle East conflicts could disrupt commercialization or supply chains.
- Dependence on licensing partners for product supply and regulatory approvals.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375311 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $8.11 | awaiting T+20 | — | $8.05 (−0.74%) |
Oct 6, 2026 21d ago | Press Release | $8.11 | awaiting T+20 | — | $8.05 (−0.74%) |
Oct 5, 2026 22d ago | 6-K | $8.11 | awaiting T+20 | — | $8.05 (−0.74%) |
Sep 17, 2026 5w ago | 6-K | $8.67 $7.83 | ▼ −9.69% | ▼ −10.89% | $8.05 (−7.15%) |
Sep 16, 2026 5w ago | EFFECT | $8.19 $7.69 | ▼ −6.11% | ▼ −9.28% | $8.05 (−1.71%) |
Sep 10, 2026 6w ago | 6-K | $7.99 $7.78 | ▼ −2.69% | ▼ −4.82% | $8.05 (+0.75%) |
Sep 3, 2026 7w ago | Press Release | $8.54 $8.00 | ▼ −6.32% | ▼ −6.93% | $8.05 (−5.74%) |
Sep 3, 2026 7w ago | 6-K | $8.54 $8.00 | ▼ −6.32% | ▼ −6.93% | $8.05 (−5.74%) |
Aug 17, 2026 10w ago | 6-K / PRESS-RELEASE | $7.76 $8.09 | ▲ +4.25% | ▲ +6.23% | $8.05 (+3.74%) |
Aug 12, 2026 10w ago | 6-K | $6.88 $7.99 | ▲ +16.13% | ▲ +18.03% | $8.05 (+17.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers